New and Emerging Treatments in Cutaneous Vasculitis

Cleveland Clinic Rheumatology

C. Langford

Checkpoint Inhibitors and Rheumatic Disease

NYU Langone

A. Bass

EADV 2023 Insights: Infectious Granulomatous Skin Diseases

EADV 2023 Insights

E. Laffitte

When Should Biologic Agents be Considered in Eosinophilic Granulomat…

Cleveland Clinic Rheumatology

M. Wechsler

Could EGPA be Treated with Biologics?

Cleveland Clinic Rheumatology

M. Wechsler

Eosinophilic Granulomatosis with Polyangiitis with Persistent Shortn…

Cleveland Clinic Rheumatology

A. Villa-Forte

EULAR 2023 Insights: Benralizumab for Eosinophilic Granulomatosis wi…

EULAR 2023 Insights

A. Bettiol

Immunomodulatory Drugs (IMIDs) Advances in Disease Pathogenesis

Cleveland Clinic Rheumatology

W. Rigby

EGPA: Look Carefully at the Heart

Cleveland Clinic Rheumatology

W. Tang

Eosinophilic Granulomatosis with Polyangiitis

Hospital for Special Surgery

A. Dua

Lupus And a New FDA Approval for EGPA

RheumNow

J. Cush

Are There Factors That Can Guide Treatment Decisions in Newly Diagno…

Cleveland Clinic Rheumatology

A. Villa-Forte

Pathergy in Patients with Bechet's Disease Receiving Laser Hair Remo…

Evidence-Based Hair

J. Donovan

Giant Cell Arteritis in the Arab Region With a Focus on Jordan

Fatima Al Naimat

Great Debate (PMR/GCA) - Upfront Use of IL-6 Inhibitors

Hospital for Special Surgery

R. Spiera, P. Seo

Behçet Syndrome Diagnosis: How and When Do Major/Minor Clinical Mani…

Haner Direskeneli

Diagnosis of Giant Cell Arteritis

Houston Methodist DeBakey Heart and Vascular Center

S. To

Behcet Syndrome Update: How Does It Manifest? When Do Symptoms Typic…

Yusuf Yazici

Abstract Discussions: Osteoporotic Fractures in Postmenopausal Women…

RheumNow

J. Pope

GCA & Steroid Weaning

RheumNow

J. Cush